BIORA THERAPEUTICS, INC. (BIOR) Net Income (Loss) Attributable to Parent USD 2019 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Biora Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2024.
  • Biora Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$4.19 M, a 76% increase year-over-year.
  • Biora Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$111 M, a 165% decline year-over-year.
  • Biora Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$124 M, a 225% decline from 2022.
  • Biora Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$38.2 M, a 84.6% increase from 2021.
  • Biora Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$247 M, a 28.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$111 M -$4.19 M +$13.3 M +76% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$124 M -$15.4 M -$1.69 M -12.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$122 M -$73.5 M -$68.3 M -1336% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$54.1 M -$17.8 M -$12.3 M -223% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-13
Q1 2023 -$41.8 M -$17.4 M -$3.63 M -26.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$38.2 M -$13.7 M +$79.2 M +85.2% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-30
Q3 2022 -$117 M -$5.11 M +$38.6 M +88.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$156 M -$5.51 M +$73 M +93% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$229 M -$13.8 M +$18.5 M +57.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$247 M -$92.9 M -$17.3 M -23% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-30
Q3 2021 -$230 M -$43.7 M +$3.32 M +7.06% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-30
Q2 2021 -$233 M -$78.5 M -$25.7 M -48.8% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-30
Q1 2021 -$208 M -$32.3 M -$15.1 M -88.1% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-30
Q4 2020 -$193 M -$75.5 M -$25.1 M -49.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 -$167 M -$47.1 M +$10.1 M +17.6% Jul 1, 2020 Sep 30, 2020 10-K 2022-03-28
Q2 2020 -$178 M -$52.8 M -$36.4 M -222% Apr 1, 2020 Jun 30, 2020 10-K 2022-03-28
Q1 2020 -$141 M -$17.2 M +$6.87 M +28.6% Jan 1, 2020 Mar 31, 2020 10-K 2022-03-28
Q4 2019 -$148 M -$50.5 M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-18
Q3 2019 -$57.1 M Jul 1, 2019 Sep 30, 2019 10-K 2021-03-18
Q2 2019 -$16.4 M Apr 1, 2019 Jun 30, 2019 10-K 2021-03-18
Q1 2019 -$24 M Jan 1, 2019 Mar 31, 2019 10-K 2021-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.